Anzeige
Mehr »
Login
Mittwoch, 26.08.2020 Börsentäglich über 12.000 News von 650 internationalen Medien
Alle ausgestochen und neuen SILBER-DISTRIKT erworben! Nächste Raketen-Stufe zündet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12HVG ISIN: US71715X1046 Ticker-Symbol: EFY 
Stuttgart
25.08.20
21:42 Uhr
0,021 Euro
-0,003
-12,50 %
Branche
Nahrungsmittel/Agrar
Aktienmarkt
Sonstige
1-Jahres-Chart
5-Tage-Chart

Aktuelle News zur PHARMACYTE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
Zeit Aktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
PHARMACYTE Aktie jetzt für 0€ handeln
13.08. PharmaCyte Biotech, Inc. - 10-K, Annual Report 6
03.08. PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer 7
29.07. PharmaCyte Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 10
29.07. PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests 243 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box...
► Artikel lesen
29.06. PharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering 9
18.05. PharmaCyte Conducts Final Audit of Mfg. Facility 11
13.04. PharmaCyte Biotech to Offer COVID-19 Testing While Creating Revenue Stream for Pancreatic Cancer Program 18
08.04. PharmaCyte Biotech enters into license agreement for COVID-19 diagnostic kits 10
08.04. BRIEF-Pharmacyte Biotech Enters License Agreement For Covid-19 Diagnostic Kits 2
08.04. PharmaCyte Biotech, Inc. - 8-K, Current Report 1
26.03. PharmaCyte Biotech CEO Discusses Navigating Testing and IND Submission During COVID-19 Pandemic 5
11.02. Will PharmaCyte Biotech's Cell-in-a-Box(R) Technology Be The Game Changer To Effectively Treating Pancreatic Cancer? 377 PCG Media covers the value that PharmaCyte's Cell-in-a-Box technology can bring to the pancreatic cancer market. Future indications expected to target diabetes and cannabinoid therapy.New York, New...
► Artikel lesen
06.02. PharmaCyte Biotech Exploits Potential Of Its Cell-in-a-Box(R) Technology; Targets Billion Dollar Cancer, Diabetes, and Medicinal Cannabinoid Markets 330 Soulstring Media Group covers how this emerging biotech can become a potential leader in treating pancreatic cancer and diabetes with its Cell-in-a-Box(R) technologyMiami Beach, Florida--(Newsfile Corp....
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3